Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies

Author(s): Joesph Mikhael, Hong Chang

Journal Name: Letters in Drug Design & Discovery

Volume 4 , Issue 2 , 2007

Become EABM
Become Reviewer


The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.

Keywords: Proteasome inhibitor, Bortezomib, Multiple myeloma, Clinical trial, Cancer

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [82 - 86]
Pages: 5
DOI: 10.2174/157018007779422541
Price: $65

Article Metrics

PDF: 1